在没有明显结构性或功能性心脏异常的患者中,E/e'比率与存活率之间的关联的修饰剂
Yishay Wasserstrum1, Rami Gilead1, Sagit Ben-Zekry1
1Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
概括
一个提升的早期心肌流波到早期透析性心肌环速度 (E/e'比率) 预测没有明显的心脏病的个体的死亡率. 这种风险在年轻的男性中较高,他们的左心室质量正常,肺动脉压力较低.
科学领域:
- 心脏病学 心脏病学
- 心声回声扫描 (Echocardiography) 是一种心声回声扫描.
- 临床研究 临床研究
背景情况:
- E/e'比率,衡量腹筋功能,因年龄和性别而异,与心力衰竭死亡率有关.
- 在没有明显心脏异常的个体中,其与死亡率的关联还没有得到很好的定义.
研究的目的:
- 在没有结构性或功能性心脏异常的患者中研究E/e'比率和全因死亡率之间的关系.
- 为了确定这种关联的潜在修饰因素.
主要方法:
- 从2009年到2021年对104,315张心声回声图进行了回顾性分析.
- 排除患有癌症,心室功能障碍,显著的膜/结构性心脏病或肺高血压的患者.
- 最终队列:32,836名患者,随访时间中位数为5.7年.
主要成果:
- 在28%的患者中观察到高E/e'比率 (>10),并与死亡率增加有关 (aHR 1.16).
- 升高的E/e'在70岁以下的个体,男性,正常左心室质量和较低肺动脉压力 (<30 mmHg) 的个体中具有显著更高的死亡风险.
结论:
- 升高的E/e'是没有明显心脏病的个体中死亡率的独立预测指标.
- 这种关联在年轻的男性中尤其明显,他们保留了左心室质量和正常的肺动脉压力,这表明它作为亚临床风险标志物的作用.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
188
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
188
Assumptions of Survival Analysis
128
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
128
Hazard Ratio
124
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
124
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Pathophysiology of Cardiac Performance
663
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
663
Cancer Survival Analysis
348
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
348


